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To report pregnancy outcomes and disease activity (DA) in women with MS, neuromyelitis
optica spectrum disorders (NMOSDs), and other neuroimmunologic diseases (ONID) after
treatment with rituximab (RTX)/ocrelizumab (OCR) 12 months before or during pregnancy.
Methods
Data were collected in the German MS and pregnancy registry and centers from the Neuro-
myelitis Optica Study Group. Sixty-eight known outcomes of 88 pregnancies from 81 women
(64 MS, 10 NMOSD, and 7 ONID) were included and stratified in 3 exposure groups: >6M-
group = RTX/OCR >6 but ≤12 months before the last menstrual period (LMP) (n = 8); <6M
group = RTX/OCR <6 months before the LMP (n = 47); preg group = RTX/OCR after the
LMP (n = 13).
Results
Pregnancy outcomes were similar between groups, but significantly more preterm births (9.8%
vs 45%) occurred after exposure during pregnancy. Overall, 2 major congenital abnormalities
(3.3%), both in the preg group, were observed. Three women had severe infections during
pregnancy. All women with MS (35) and 12/13 women with NMOSD, RTX/OCR exposure
before the LMP and known pregnancy outcomes after gestational week 22 were relapse free
during pregnancy. Five of 29 (17.2%) women with relapsing-remittingMS (RRMS) and 1 of 12
(8.3%) with NMOSD and at least 6 months postpartum follow-up experienced a relapse
postpartum. Duration of RTX/OCR and early retreatment but not detection of B-cells were
possible predictors for postpartum relapses in patients with RRMS/NMOSD.
Conclusions
Although RTX/OCR might be an interesting option for women with RRMS/NMOSD who
plan to become pregnant to control DA, more data on pregnancy outcomes and rare risks are
needed.
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Only limited (<200) data on pregnancy outcomes after anti-
CD20 monoclonal antibodies (mAbs) exposure—mainly
focusing on rituximab (RTX)—in women with neuro-
immunologic diseases have been published.1–3 Because of the
fear of potential fetal B-cell depletion, the label is conservative
and recommends to discontinue anti-CD20 mAbs at least 6
(US Food and Drug Administration) to 12 months (Euro-
pean Medicine Agency) before planned conception.
With the introduction of highly effective disease-modifying
therapies (DMTs), women with relapsing-remitting MS
(RRMS) or neuromyelitis optica spectrum disorders
(NMOSDs) might consider pregnancy after stabilization of
active disease courses,4–6 but reoccurrence or even rebound
of disease activity (DA) has been reported in patients with
MS after discontinuation of DMTs such as natalizumab and
fingolimod.7–12 Thus, women may be confronted weighing
the risk of relapses against potential risks of fetal DMT
exposure.13 In NMOSD, relapses during pregnancy and
postpartum have been reported, particularly in patients
who stopped immunosuppressive therapy, and mainte-
nance of immunotherapy has been discussed.14,15 Anti-
CD20 mAbs could be an interesting option as in contrast to
other drugs, no rebound has been reported so far.2,16
Therefore, the objective of this cohort study was to investigate
the safety of RTX/ocrelizumab (OCR) during the last 12
months before or during pregnancy in women with neuro-
immunologic diseases and to assess DA in a subcohort of
women with RRMS or NMOSDs.
Methods
Participants and data collection
We identified 88 pregnancies of 81 women with neuro-
immunologic diseases treated with RTX or OCR ≤12
months before the last menstrual period (LMP) through
the German MS and pregnancy registry (DMSKW) and
centers from the Neuromyelitis Optica Study Group
(NEMOS) network between November 2004 and Febru-
ary 2020 (figure). In the DMSKW, pregnant women with
MS or other neuroimmunologic diseases (ONID) are en-
rolled at any time point during pregnancy and followed up
prospectively with a standardized questionnaire.17 For
pregnancies reported from NEMOS centers, we used a core
minimal data set from the DMSKW consisting of the fol-
lowing variables: diagnosis, age, LMP, date of last RTX/
OCR infusion before or after the LMP, pregnancy
outcome, severe maternal and infant infections, relapses
during pregnancy, and postpartum in patients with RRMS/
NMOSD. Four pregnancies (1 PPMS, 1 NMOSD, and 2
ONID) from NEMOS centers were included retrospec-
tively (all 4 with healthy newborns). Available B-cell counts
from mothers and babies were collected. We stratified our
cohort according to exposure to anti-CD20 mAbs before or
after the LMP into 3 groups: >6M group = RTX/OCR >6
but ≤12 months before the LMP; <6M group = RTX/OCR
<6 months before the LMP; preg group = RTX/OCR after
the LMP.
Outcomes
Spontaneous abortion (SA) was defined as fetal loss before
22 completed gestational weeks (GWs). Congenital
anomalies (CA) were rated and classified in accordance
with the guidelines of EUROCAT and confirmed by the
treating pediatrician/obstetrician. Birth weight and length
and preterm birth (PB, live birth before 37 completed
GWs) were analyzed as reported in mothers’ maternity
logs. Elective abortions (EAs) and ectopic pregnancies
were also documented. B-cells, depletion in newborns was
defined as not detectable B-cells, borderline as detectable
but under the lower range of the reference.
In the subgroup of women with RRMS/NMOSD, the
number of relapses before, during, and after pregnancy
(follow-up 6 months) was analyzed using the current
McDonald criteria relapse definition18 and disability pro-
gression12 by using the Expanded Disability Status Scale
(EDSS).19 Except one, the EDSS was taken outside relapse
(≥2 months). The baseline EDSS was the last available
EDSS during the last year before pregnancy and without
the occurrence of a relapse between the EDSS date and the
LMP. Relapses were confirmed, and the EDSS was
obtained by the treating neurologist.
Standard protocol approvals, registrations,
and patient consents
All patients gave their informed consent. The DMSKW is
approved by the review board of the Ruhr University in
Bochum (Reg Nr.: 18-6474-BR). All patients who partici-
pated in the NEMOS gave written informed consent, and
each local institutional review board of participating centers
approved the study.
Statistical analysis
To compare pregnancy outcomes as well as relapses and dis-
ability progression during pregnancy and postpartum between
Glossary
CA = congenital anomalies; DA = disease activity; DMT = disease-modifying therapy; EA = elective abortion; EDSS =
Expanded Disability Status Scale; GW = gestational week; LMP = last menstrual period; mAb = monoclonal antibody;
NEMOS = Neuromyelitis Optica Study Group; NMOSD = neuromyelitis optica spectrum disorder; OCR = ocrelizumab;
ONID = other neuroimmunologic diseases; RRMS = relapsing-remitting MS; RTX = rituximab; SA = spontaneous abortion.
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groups, we used the Kruskal-Wallis rank-sum test for continuous
and the χ2 test or Fisher exact test for categorical variables. A
2-sided p < 0.05 was considered as statistically significant.
Pregnancy outcomes were analyzed regardless of the un-
derlying disease. To account for the difference in being at risk,
we used different denominators: all known pregnancy
Figure Flowchart of the pregnancies enrolled in the study
*ONID included in this cohort: 1 myasthenia gravis, 1 autoimmune myositis, 1 neurosarcoidosis, 1 MOG disease, 1 CRION, 2 NMDA-Ab encephalitis.
CRION = chronic relapsing inflammatory optic neuropathy; DMSKW = German MS and pregnancy registry (Deutsches Multiple Sklerose und Kinderwunsch
Register); DMT= disease-modifying therapy;GW= gestationalweek;mAb=monoclonal antibody;MOG=myelinoligodendrocyteglycoprotein;NEMOS=Neuromyelitis
Optica StudyGroup; NMOSD= neuromyelitis optica spectrumdisorder; ONID = other neuroimmunologic diseases; PPMS = primary progressiveMS; RRMS= relapsing-
remitting MS; SPMS = secondary progressive MS
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outcomes for the outcomes live birth, SA, and EA and all live
births for the outcomes CA and PB. In addition, we performed
four sensitivity analysis with (i) prospective pregnancies and (ii)
patients with MS and NMOSD (ONID excluded). We also
stratified exposure (iii) by drug RTX/OCR or (iv) by timing <3
months, >3 but ≤12 months before the LMP, or after LMP.
For all analysis of DA, we stratified our cohort into patients with
RRMS and NMOSD. The analysis of DA during pregnancy only
includes pregnancies with outcome after 22 GWs and treated
with anti-CD20 mAbs already before pregnancy. The analysis of
DA postpartum includes all pregnancies with anti-CD20 mAbs
before or during pregnancy and a postpartum follow-up of 6
months (figure). Statistical analysis was performed using RStudio
Version 1.2.5019.
Data availability
No deidentified patient data will be shared. No study-related
documents will be shared. Reasonable requests from any
qualified investigator for anonymized data will be considered
by the corresponding author.
Results
Baseline characteristics
We analyzed 49 (55.7%) pregnancies after treatment with
RTX and 39 (44.3%) after therapy with OCR. Most
pregnancies occurred in women with MS (n = 64, 72.7%;
n = 39 OCR and n = 25 RTX) or NMOSD (n = 17, 19.3%),
and 7 (8.0%) in women with ONID (figure), the majority
(n = 64, 72.7%) within 6 months after the last infusion
administered with a median of 67 days before the LMP
(range 4–169 days).
Fourteen pregnancies (15.9%) were exposed after the LMP
(median 39 days, range 2–148 days), but only 4 because of
worsening of the underlying autoimmune disease (RRMS,
NMOSD, and chronic relapsing inflammatory optic neuropa-
thy and myositis). One woman (NMOSD) followed her rou-
tine infusion scheme, and the remaining (n = 9) were infused
during early pregnancy because pregnancy was undetected.
Five of these 14 (35.7%) were treated with anti-CD20 mAbs
for the first time during pregnancy: 2 because of a relapse, 1 due
to worsening of myositis, and 2 due to undetected pregnancies.
Two pregnancies (1 RRMS and 1 NMOSD) were exposed
simultaneously to another DMT (1 fingolimod and 1 aza-
thioprine). Two (1 NMOSD and 1 myositis) received con-
comitant low-dose steroid therapy during pregnancy and 3 (1
RRMS and 2 NMOSD) high-dose corticosteroids for relapse
treatment during pregnancy. Baseline characteristics of all
pregnancies are shown in table 1.
Pregnancy outcomes
We analyzed the outcomes of 67 pregnancies (76.1%) in-
cluding 1 twin pregnancy, most resulting in live births
(n = 60/68; 88.2%) (table 2). Twenty-one (23.9%) preg-
nancies are still ongoing. The overall number of SAs (n = 5/68;
7.4%) was low regardless if reported by the DMSKW or by
NEMOS centers. Overall, 15% of pregnancies ended in PB,
significantly more often in those exposed during pregnancy
(>6M group: 0/8; <6M group: 4/41 9.76%; preg group: 5/11
45.45%: p value: 0.019, table 2). Excluding PB, the birth weight
was statistically not significantly lower in the preg group. PB
occurred in median GW 35 (range 29.14–36.14), and preterm
newborns had a mean birth weight of 2,308.13 ± 534.50 g.
Potential reasons for PB are shown in table e-1, links.lww.com/
NXI/A338.
Two of 60 live births (3.3%) were born with a major CA,
both (a ventricular septum defect and an atrium septum
defect with pulmonary stenosis) in the preg group (2/11,
18.2%, p value = 0.046) (table e-1, links.lww.com/NXI/
A338). Three (4.4%) EAs due to social indication were
performed.
Additional sensitivity analysis with a more conservative ex-
posure cutoff of 3 months (see above Statistical analysis)
replicated our findings concerning major CA (>3M group: 0/
19; <3M group: 0/30; preg group: 2/11 18.2%: p value:
0.034) and PB (>3M group: 1/19 5.3%; <3M group: 3/30
10.0%; preg group: 5/11 45.4%: p value: 0.020). Excluding
retrospective cases and ONID does not change the results.
After stratification of exposure by drug (RTX or OCR), no
statistically significant differences can be observed for major
CA and PB (data not shown).
B-cell counts in newborns
B-cell counts were available for 14 babies (23.4%), 12 with
1 (9 cord blood, 2 during the first weeks of live, and 1 at age
3 months) and 2 with 2 B-cell counts (cord blood/2 and 5
months postpartum, respectively). B-cells according to
anti-CD20 mAb exposure are shown in table 2. Despite
exposure 6 months before the LMP (n = 8) or during
pregnancy (n = 4), most had normal B-cell counts. Four
(28.6%) newborns showed borderline B-cell counts (RTX
50 days before the LMP, 325 (ref. 600–1,000)/μL, 10 (ref.
13–39)%; OCR 99 days before the LMP, 420 (ref.
150–1,200)/μL, 9.1 (ref. 15–40)%; RTX 200 days before
the LMP, 47 (ref. 50–631)/μL, 2 (ref. 5–24)%; and OCR
131 days after the LMP 339 (ref. 600–1,900)/μL, 12 (ref.
4–26)%). In the OCR-exposed baby, B-cells normalized at
age 2 months (1,107 [ref. 600–3,000]/μL, 15 [ref.
13–39]%) despite OCR exposed breastfeeding.20 The B-
cell–depleted newborn was exposed to RTX 141 days after
the LMP and azathioprine until GW 7. At age 5 months,
the B-cell count was normal and no serious infections were
observed in 20 months of follow-up.
Breastfeeding
Of 57 women with available information on breastfeeding,
38 breastfed exclusively (n = 20/52.6%) or partly (n = 18/
47.4%) for a median duration of 119 days (range 1–205
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days). Three of them received anti-CD20 mAbs during
breastfeeding, with a duration of exposed breastfeeding of
82, 54, and 53 days recently reported in Ref. 20.
Infections in mothers and infants
Severe infections during pregnancies occurred in 3mothers (2
with decreased/depleted B-cells) and infections leading to
Table 1 Baseline characteristics of all 88 pregnancies
>6M group, n = 10 <6M group, n = 64 Preg group, n = 14 p Value
Disease: MS/NMOSD/ONID, n 6/3/1 49/11/4 9/3/2 —
Exposure RTX/OCR, n 7/3 36/28 6/8 —
Age at conception, mean (±SD), y 29.63 (4.41) 31.53 (4.88) 30.80 (6.79) 0.492a
GW at first contact, mean (SD) 16.34 (13.44) 11.50 (8.75) 18.41 (21.00) 0.497a
Disease duration, mean (±SD), y 6.82 (5.94) 7.35 (4.83) 4.50 (3.51) 0.098a
No. of DMTs before RTX/OCR, median (range) 1.5 (0–5) 2 (0–8) 2.5 (0–6) 0.676a
No. of cycles RTX/OCR, median (range) 4 (1–21) 3 (1–21) 3 (2–14) 0.886a
BMI, mean (±SD), kg/m2 24.49 (3.95) 23.85 (5.51) 24.87 (4.78) 0.515a
Smoking during first trimester, n (%) 0 8 (12.5) 1 (7.14) 0.728b
Alcohol during pregnancy, n (%) 0 1 (1.56) 1 (7.14) 0.454b
Abbreviations: BMI = body mass index; DMT = disease-modifying therapy; GW = gestational week; LMP = last menstrual period; n = number of women;
OCR = ocrelizumab; Preg group = RTX/OCR after the LMP; RTX = rituximab; NMOSD = neuromyelitis optica spectrum disorder; >6M group = RTX/OCR >6 but
≤12 months before the LMP; <6M group = RTX/OCR <6 months before the LMP.
a Comparison with the Kruskal-Wallis rank-sum test between the 3 groups.
b Ccomparison with the Fisher exact test between the 3 groups.
Table 2 Pregnancy outcomes in 67 pregnancies with known pregnancy outcome
>6M group, n = 8 <6M group, n = 47 Preg group, n = 13a p Value
Live birth, n (%) 8 (100.00) 41 (87.23) 11a (84.62) 0.528b
Spontaneous abortion, n (%) 0 4 (8.51) 1 (7.69) 1.000c
Elective abortion social indication, n (%) 0 2 (4.26) 1 (7.69) 0.677c
Major congenital abnormalities, n (%) 0 0 2 (18.18) 0.046c
Preterm birth, n (%) 0 4 (9.76) 5 (45.45) 0.019c
Gestational week at birth, mean (±SD) 40.68 (0.89) 39.13 (2.47) 37.81 (3.09) 0.021d
Birth weight, mean (±SD), g 3,496.25 (445.14) 3,251.25 (661.46) 2,839.50 (620.13) 0.087d
Birth weight (excluding preterm birth), mean (±SD), g 3,496.25 (445.14) 3,368.89 (560.58) 3,116.67 (547.54) 0.506d
Birth length, mean (±SD), cm 52.63 (2.33) 51.21 (3.24) 49.15 (4.30) 0.127d
Newborns with borderline B-cells n/a (%) 1/2 (50.00) 2/8 (25.00) 1/4 (25.00) 1.000c
Newborns with depleted B-cells n/a (%) 0/2 0/8 1/4 (25.00) 0.429c
Pregnancies with severe infections, n (%) 0 2 (4.26) 1 (7.69) 0.677c
Infant infections leading to hospitalization, n (%) 0 2 (4.26) 1 (7.69) 0.677c
Abbreviations: a = available number of newborns; LMP = last menstrual period; n = number of pregnancies/newborns; Preg group = RTX/OCR after the LMP;
<6M group = RTX/OCR <6 months before the LMP; >6M group = RTX/OCR >6 but ≤12 months before the LMP.
Bold text indicates p value < 0.05.
a Including twins.
b Comparison with the χ2 test between the 3 groups.
c Comparison with the Fisher exact test between the 3 groups.
d Comparison with the Kruskal-Wallis rank-sum test between the 3 groups.
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hospitalization in 3 newborns (table 2 and table e-2, links.lww.
com/NXI/A338).
Relapses and disability progression during
pregnancy and postpartum in women
with RRMS
All pregnancies in women with RRMS (n = 35), anti-CD20
mAbs before conception, and known pregnancy outcomes
after GW 22 were relapse free (table 3).
For 5 of 29 pregnancies (17.2%), a relapse during the first 6
months postpartum (median time to first relapse postpartum
2.3 months; range 0.1–4.9 months) was documented. The
majority (n = 21, 72.4%) restarted DMT (all anti-CD20
mAbs) with a median time of 3.0 months (range 0.3–26.0
months) after birth (median DMT-free interval 14.1 months,
range 5.2–35.6). Only 1 woman had a relapse 44 days after the
infusion withOCR, 69 days after delivery (table e-3, links.lww.
com/NXI/A338). The median time between the last RTX/
OCR and the relapse postpartum was 16.3 months (range
1.5–21 months).
The baseline EDSS (median 2.5, range 0–5) was evaluated
median 33 days before the LMP (range 17–250) and the delta
EDSS analyzed in 32/35 (91.4%; median 0, range −2 to 0)
during pregnancy and 16/29 (55.2%; median 0 range −2 to
0.5) postpartum (table 3 and table e-3, links.lww.com/NXI/
A338). All but 1 woman (autoimmune myositis) with ONID
showed a stable DA during pregnancy without change of
therapy.
Relapses and disability progression during
pregnancy and postpartum in women
with NMOSD
Most pregnancies (n = 12/13; 92.3%) in women with
NMOSD, anti-CD20 mAbs before conception, and known
pregnancy outcomes after GW 22 were relapse free (table 3).
Only 1 woman had a relapse in GW 33 despite having re-
ceived RTX before and during pregnancy. She had reduced
her previous concomitant prednisolone therapy after notice of
pregnancy. One woman started anti-CD20 mAbs during
pregnancy because of a disastrous relapse with an EDSS in-
crease from 2 to 7 after withdrawal of azathioprine at the
beginning of pregnancy.
For one of 12 pregnancies (8.3%), 2 relapses during the first 6
months postpartum (time to first relapse postpartum 0.3
months) were documented (table 3 and table e-3, links.lww.
com/NXI/A338). All restarted anti-CD20 mAbs with a me-
dian time of 0.45 months (range 0–4.2 months) after birth
(median DMT-free interval 13.2 months, range 6.3–18.8).
The baseline EDSS (median 3; range 1.5–4) was evaluated
median 120 days before the LMP (range 5–308) and delta
EDSS analyzed in 11/13 (84.6%, median 0 range −1 to 0.5)
during pregnancy and 12/12 (100%; median 0 range −0.5 to
2.5) postpartum. The EDSS remained stable during
pregnancy in all patients. Postpartum, all but 1 (11/12;
91.7%) patients with NMOSD showed a stable EDSS. This
patient received RTX for the first time during pregnancy due
to a disastrous relapse and had 2 relapses during the second
half of the postpartum year (table 3).
Relapses in patients with RRMS and NMOSD
depending on the B-cell count
For analysis of DA during pregnancy, we had 12 (25.0%) B-cell
counts of 48 included pregnancies available. Most (9; 75.0%) had
detectable B-cells in peripheral blood during pregnancy, only 1
(NMOSD) of them relapsed. Postpartum, 9 (22.0%) B-cell
counts—all of them before the first anti-CD20mAb infusion after
delivery—from 41 pregnancies were available and detectable in all
of them, 3 (2RRMSand 1NMOSD)of thesewomen relapsed. In
3 women with MS with postpartum relapses, B-cell counts were
not available.
Predictors for postpartum relapses in patients
with RRMS and NMOSD
Women (RRMS/NMOSD) without postpartum relapses had
received anti-CD20 mAbs for a longer time with more cycles
and were retreated earlier postpartum than those who re-
lapsed (table 4). However, this difference was not statistically
significant.
Discussion
In our cohort study, we found that pregnancy outcomes
after treatment with anti-CD20 mAbs in the year before
pregnancy in women with neuroimmunologic diseases
were within the range what is expected for the general
population. If anti-CD20 mAbs were given during preg-
nancy, we observed significantly more PBs and 2 major
CAs. Another important finding of our study is the good
control of DA during pregnancy (98%) and postpartum
(85%), observed in most pregnancies in women with
RRMS/NMOSD, although treatment was generally sus-
pended during pregnancy.
In contrast to a recently published study from southern Cal-
ifornia with similar sample size, where 27% of the women had
SA,2 we did not observe an increased risk. In this population-
based study of a health insurance where data linkage to the
gynecologic records is possible, pregnancies are captured very
early. In our study, first contact was at the beginning of the
second trimester, after the risk for SA is already decreasing, a
common limitation in pregnancy registries.21
The overall prevalence of major CA was 3.3% (n = 2), both
in women who were treated with OCR during pregnancy,
which is in line with outcomes from unexposed pregnan-
cies from our DMSKW registry.17 RTX or OCR exposure
was not associated with teratogenicity in humans,1,3 nor in
animal studies22,23 so far, and we believe that it is a chance
finding.
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Although the overall risk of PB was similar to other
studies,2,24 we found a higher risk for PB (45%) and lower
birth weight when anti-CD20 mAb was given during preg-
nancy. This might be partially related to the underlying
disease and/or concomitant autoimmune diseases,25 espe-
cially in NMOSD, to the previous DMT exposure and/or
other concomitant medication with steroids, and deserves
further investigation. To what extent long-term treatment
with anti-CD20mAbsmay lead to hypogammaglobulinemia,
which in turn could increase the risk of neonatal and ma-
ternal infections26,27 including chorioamnionitis—another
potential underlying mechanism of PB—is still unknown.
Recently, it was shown that treatment with RTX increases
the risk of infections in the general MS population.28 We did
not collect systematically information on IgG levels, but 3
women experienced severe infections potentially attribut-
able to B-cell depletion.
In most women who were treated during pregnancy, anti-
CD20 mAbs were given early during the first trimester, sug-
gesting that only limited amounts of the drugs passed through
the placental barrier and fetal exposure was low.29 So far, data
on B-cell counts in the newborn, especially frommothers with
MS or NMOSD, are based on single case reports.30 In our
study, B-cell counts were normal in the majority (73%) of the
babies, of note also in 2 first trimester exposed babies. Four
babies were born with borderline values, but determination of
B-cell counts in those newborns was not standardized and the
exact methods used unknown. The fact that one newborn was
B-cell depleted after pregnancy exposure to RTX during the
second trimester is in line with previous reports and indicates
that treatment after the second trimester is a risk factor for
neonatal B-cell reduction. This should require the measure-
ment of B-cells at birth and a close interaction with pedia-
tricians to time vaccinations accordingly.1,31
Our data that all women with RRMS who had been treated
with anti-CD20 mAbs before pregnancy experienced a
stable DA during pregnancy are very reassuring and in line
with a recent observation in a retrospective cohort of 27
patients with MS from Sweden16 and both Californian
studies.1,2 Of note, women who were treated >6 months
before the LMP were effectively untreated by the end of
pregnancy.
Although more women with RRMS in our cohort (17,2%)
relapsed postpartum compared with the southern Cali-
fornian study (2.7%), our results still demonstrate a very
good control of DA specially in comparison to other active
MS pregnancies, e.g., after the suspension of natalizumab
(36.5% relapsed during pregnancy and 21.7% in the first
postpartum year).12 Reasons for the higher number of
postpartum relapses in our patients with RRMS may in-
clude the close prospective follow-up of our patients as
well as a more active disease cohort, which is reflected by
the high number of previous DMTs in 4 RRMS patients
with relapses. As B-cells were detectable in 2 women with
RRMS who relapsed but also in 4 women without
Table 3 Relapses during pregnancy and postpartum in pregnancies in women with RRMS and NMOSD

















Pregnancies with outcomes after GW 22 and anti-CD20
mAbs before pregnancy, n
4 28 3 — 3 8 2 —
Pregnancies with relapses during pregnancy, n (%) 0 0 0 — 0 0 1
(50.00)
0.154a
Pregnancies with high-dose steroid exposure, n (%) 0 0 0 — 0 0 1
(50.00)
0.154a




2 (0–3.5) 0.629b 3 (2–3) 3
(1.5–4)
3 (3–3) 0.774b
Pregnancies with disability progression during pregnancy,
n/a (%)
0/4 0/25 0/3 — 0/3 0/7 0/1 —
RRMS, n = 29 NMOSD, n = 12
Pregnancies with 6 mo postpartum follow-up, n 3 24 2 — 3 7 2 —
Pregnancies with relapses up to 6 mo pp, n (%) 1 (33.33) 4 (16.67) 0 0.642a 0 1 (14.29) 0 1.000a
Pregnancies with disability progression up to 6 mo pp, n/a (%) 0/3 0/11 0/2 — 0/3 0/7 1/2 (50.00) 0.167a
Abbreviations: a = number of women with available EDSS; anti-CD20-mAb = anti-CD20 monoclonal antibody; EDSS = Expanded Disability Status Scale;
GW = gestational week; LMP = last menstrual period; mo = months; n = number of women; NMOSD = neuromyelitis optica spectrum disorder; pp =
postpartum; Preg group = RTX/OCR after the LMP; RRMS = relapsing-remitting MS; >6M group = RTX/OCR >6 but ≤12 months before the LMP; <6M group =
RTX/OCR <6 months before the LMP.
a Comparison with the Fisher exact test between the 3 groups.
b Comparison with the Kruskal-Wallis rank-sum test between the 3 groups.
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postpartum relapses, the reoccurrence of B-cells did not
seem to predict these relapses.
In our cohort, women with NMOSD had a surprisingly low
relapse risk, although relapse rates are known to increase
after delivery in this disease spectrum15,32,33 or perhaps
already during pregnancy.14 Because of the low number of
relapses, we were not able to identify significant risk factors
for recurrent DA. So far, suspension of immunosuppres-
sion has been identified as the main risk factor for relapses
during pregnancy and postpartum,14 which is reflected by
the 1 case in our cohort with the disastrous relapse during
pregnancy after withdrawal of azathioprine and before
start with RTX. In addition, the presence of B-cells in the
peripheral blood has been associated with NMOSD re-
lapses in previous studies,34 which is partly supported by
our observations because 3 relapses occurred all in women
with detectable B-cells.
Although nonsignificant, we identified the overall treat-
ment duration with anti-CD20 mAbs and number of RTX/
OCR cycles before pregnancy and the later reinfusion
postpartum as possible risk factors for postpartum relapses
in patients with RRMS/NMOSD. Thus, women with ac-
tive disease before pregnancy might benefit from
postponing pregnancy until stabilization of DA and re-
suming anti-CD20 mAbs early after delivery, but more data
are needed to give a definite advice.
Recent publications deliver reassurance for the use of mAbs
during breastfeeding in neuroimmunologic diseases.35 The
amount of RTX in the breast milk was shown to be minimal.
Data onOCR transfer are not available yet but can be anticipated
to be very low.36 Even if not officially labeled, we believe that
women should not forego nursing of mature newborns because
of anti-CD20mAbs, but again, more data with a longer follow-up
of the children are needed.
Beside the short follow-up time, our study has other limitations:
importantly, our data are limited by a relatively small sample size,
which precluded a more detailed, multivariable adjusted analysis,
especially as adverse pregnancy outcomes and in our cohort also
relapses were rare events. The fact that 2 neonatal strokes have
been reported recently after anti-CD20 mAb therapy2,37 under-
lines the importance of a systematic collection of data and if
possible a combined analysis between different registries to in-
crease sample size in the future. In our cohort, the treatment
duration with OCR before pregnancy is still short because it was
only approved inGermany for RRMS in early 2018, an important
limitation if the risk for infection increases with longer use. In
Table 4 Comparison of pregnancies in patients with RRMS/NMOSD with and without documented relapses during the
postpartum period
Pregnancies with postpartum
relapse, n = 6
Pregnancies without postpartum
relapse, n = 35
p
Value
RRMS/NMOSD, n 5/1 24/11 —
Exposure RTX/OCR, n 5/1 25/10 0.651a
Age, mean (SD), y 31.90 (5.38) 31.30 (4.65) 0.883b
Disease duration, mean (SD), y 8.11 (5.26) 6.88 (4.79) 0.417b
No. of DMTs before RTX/OCR, median (range) 3.5 (1–6) 1 (0–8) 0.108b
Duration of RTX/OCR treatment before the LMP, median
(range), mo
0.25 (0–35.17) 12.77 (0–146.34) 0.205b
No. of RTX/OCR cycles before the LMP, median (range) 1 (1–7) 2 (1–13) 0.157b
No. of relapses in the year before the LMP, median (range) 0 (0–2) 0 (0–2) 0.782b
Pregnancies with RTX/OCR restart pp, n (%) 5 (83.33) 28 (80.00) 1.000c
Total duration of anti-CD20 mAb treatment-free interval,
median (range), mo
13.80 (10.80–25.50) 13.90 (5.17–35.57) 0.744b
Time to RTX/OCR restart pp, median (range), mo 4.07 (0.83–14.13) 2.47 (0–26.00) 0.248b
Pregnancies in women with detectable B-cells any time
during 6 mo pp, n/a (%)
3/3 (100) 6/6 (100) 0.317c
Pregnancies in women breastfeeding exclusively, n (%) 2 (33.33) 12 (34.29) 1.000a
Abbreviations: a = available number of women with B-cell counts; DMT = disease-modifying therapy; LMP = last menstrual period; mo =months; n = number
of women; NMOSD = neuromyelitis optica spectrum disorder; OCR = ocrelizumab; pp = postpartum; RTX = rituximab; RRMS = relapsing-remitting MS.
a Comparison with the Fisher exact test regarding RTX exposure between the 2 groups.
b Comparison with the Kruskal-Wallis rank sum test between the 2 groups.
c Comparison with the χ2 test between the 2 groups.
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addition, we only have limited information on the health status of
the infants at birth such as the Apgar score and long-term out-
comes of the babies including developmental milestones, all in-
fections, vaccinations, and systematic data on B-cells.
Nonetheless, our study has strengths, among them is the inclusion
of the largest cohort of RTX-treated women with NMOSD, the
possibility to stratify for 3 different exposure groups, and at least in
some women and babies, the availability of B-cell counts.
Our findings demonstrate that anti-CD20 mAbs are highly ef-
fective for disease control in women with RRMS and NMOSD
during and also partly after pregnancy and no major safety signal
was observed after use within 6 months before conception. This
finding is biologically plausible as the placental transfer for mAbs
during the first trimester is negligible.38 Anti-CD20 mAbs offer
advantages for women with neuroimmunologic diseases, espe-
cially with active RRMS/NMOSDwhowant to get pregnant due
to its long-lasting effects. Both RTX and OCR are interesting
options as the drugs themselves are cleared within 4–6 months
after exposure, but the biological effect seems to continue. Be-
sides, B-cell monitoring for the mothers and newborns long-term
data and data from larger patient cohorts are necessary to de-
termine the safety profile and identify the best time point when to
restart after delivery. Especiallymore information on the infection
risk during and after pregnancy in association with serum im-
munoglobulin levels in the mother and child is needed. There-
fore, most importantly, outcome on pregnancies after anti-CD20
mAbs should be all carefully documented in registries, especially
in rare diseases such as NMOSD.
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T. Kümpfel received speaker honoraria from Bayer Health-
Care, Merck, Novartis Pharma, Roche Pharma, and Biogen as
well as grant support from Novartis. S. Thiel received speaker
honoraria from Bayer HealthCare. I. Meinl received travel
expenses from MedDay and Roche Pharma and compensa-
tion from Serono and Roche Pharma. A.I. Ciplea received
speaker honoraria from Bayer HealthCare and travel grants
from Sanofi Genzyme, Teva, and Novartis. A. Bayas received
personal compensation from Merck Serono, Biogen, Bayer,
Novartis, Teva, Roche, Sanofi/Genzyme, Celgene, and Alex-
ion and grants for congress trips and participation from Bio-
gen, Teva, Novartis, Sanofi/Genzyme, Merck Serono, and
Celgene. F. Hoffmann received speaker honoraria and grant
support from Alexion, Bayer Vital, Biogen, CSL Behring,
DIAMED Medizintechnik, Genzyme, Grifols, Ipsen, Merck
Serono, Novartis, Roche, and Teva. U. Hofstadt-van Oy re-
ceived speaker honoraria from Merck and Bayer HealthCare
and research support by unrestricted grants from Bayer
Schering, Novartis, and Merck. M. Hoshi received travel ex-
penses and speaker honoraria from Bayer HealthCare, Merck,
Sanofi-Aventis/Genzyme, and Biogen. J. Kluge declares no
potential conflicts of interest with respect to this article. M.
Ringelstein received speaker honoraria from Novartis, Bayer
Vital GmbH, Roche, Alexion, and Ipsen and travel re-
imbursement from Bayer Schering, Biogen Idec, Merz, Gen-
zyme, Teva, Roche, and Merck, none related to this study. O.
Aktas reports grants from the German Ministry of Education
and Research (BMBF), outside of the submitted work, and
personal fees from Bayer HealthCare, Biogen, Merck Serono,
Novartis, Roche, Teva, Alexion, andMedImmune, outside of the
submitted work. M. Stoppe declares no potential conflicts of
interest with respect to this article. A. Walter received travel
expenses and speaker honoraria from Bayer HealthCare, Teva
Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme,
Biogen, and Roche Pharma. M.S. Weber receives research sup-
port from the Deutsche Forschungsgemeinschaft (DFG; WE
3547/5-1), Novartis, Teva, Biogen Idec, Roche, Merck, and the
ProFutura Programmof theUniversitätsmedizinGöttingen.M.S.
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